Delivering on the Promise of Technology to Augment Behavioral Interventions in Type 2 Diabetes
Individuals with type 2 diabetes face a myriad of daily self-management decisions, encompassing diet, exercise, medication, and glucose monitoring. These behaviors influence outcomes such as hemoglobin A1c (HbA1c) and body weight, which in turn drive longer-term complications. Accordingly, enhanced support for positive self-care behaviors is a priority to promote health and well-being in the context of type 2 diabetes. (Source: Diabetes Care)
Source: Diabetes Care - April 26, 2023 Category: Endocrinology Source Type: research
Response to Comment on Duarte et al. Systematic Review and Network Meta-analysis of Neurostimulation for Painful Diabetic Neuropathy. Diabetes Care 2022;45:2466 –2475
Sharan et al. (1) and Sadeghirad et al. (2) raise important points regarding the data sets used in our article (3) and whether a network meta-analysis (NMA) is appropriate. We appreciate the opportunity to respond. (Source: Diabetes Care)
Source: Diabetes Care - April 26, 2023 Category: Endocrinology Source Type: research
Issues and Events
(Source: Diabetes Care)
Source: Diabetes Care - April 26, 2023 Category: Endocrinology Source Type: research
Comment on Bezin et al. GLP-1 Receptor Agonists and the Risk of Thyroid Cancer. Diabetes Care 2023;46:384 –390
We read with great interest the article by Bezin et al. (1). Glucagon-like peptide 1 receptor agonist (GLP-1 RA) exposure in rodents is associated with thyroid C-cell hyperplasia, tumor formation, and calcitonin secretion. Using the French national health care insurance database, the authors conducted a nested case-control analysis to determine the risk of thyroid neoplasm among individuals with type 2 diabetes treated with a GLP-1 RA. A total of 2,562 case subjects with thyroid cancer and 45,184 control subjects were included. The use of GLP-1 RA for 1 –3 years was associated with an increased risk of thyroid cancer w...
Source: Diabetes Care - April 26, 2023 Category: Endocrinology Source Type: research
In This Issue of Diabetes Care
(Source: Diabetes Care)
Source: Diabetes Care - April 26, 2023 Category: Endocrinology Source Type: research
Comment on Bezin et al. GLP-1 Receptor Agonists and the Risk of Thyroid Cancer. Diabetes Care 2023;46:384 –390
With interest, we read the article by Bezin et al. (1), where a case-control study was reported that demonstrated increased risk of thyroid cancer among users of glucagon-like peptide 1 receptor agonists (GLP-1 RAs). (Source: Diabetes Care)
Source: Diabetes Care - April 26, 2023 Category: Endocrinology Source Type: research
Response to Comment on Bezin et al. GLP-1 Receptor Agonists and the Risk of Thyroid Cancer. Diabetes Care 2023;46:384 –390
Agence Nationale de S écurité du Médicament et des Produits de Santé10.13039/5011000075432019S015 (Source: Diabetes Care)
Source: Diabetes Care - April 26, 2023 Category: Endocrinology Source Type: research
Response to Comment on Tang et al. The Impact of Carbamylation and Anemia on HbA 1c ’s Association With Renal Outcomes in Patients With Diabetes and Chronic Kidney Disease. Diabetes Care 2023;46:130–137
National Institute of Diabetes and Digestive and Kidney Diseases10.13039/100000062R01DK124453American Heart Association10.13039/100000968AHA23POST1010825 (Source: Diabetes Care)
Source: Diabetes Care - April 26, 2023 Category: Endocrinology Source Type: research
Comment on Bezin et al. GLP-1 Receptor Agonists and the Risk of Thyroid Cancer. Diabetes Care 2023;46:384 –390
A recent issue of Diabetes Care included a population-based case-control study by Bezin et al. (1) that has set off an alarm for diabetologists around the world. Bezin et al. attempted to address the issue of whether glucagon-like peptide 1 receptor agonists (GLP-1 RAs) were associated with thyroid cancer (TC) by using data from the French nationwide health care insurance system database. They looked at risk for TC according to GLP-1 RA use and cumulative duration of use. They showed that use of GLP-1 RAs for 1 –3 years was associated with increased risk of all TC (adjusted hazard ratio 1.58, 95% CI 1.27–1.95) and medu...
Source: Diabetes Care - April 26, 2023 Category: Endocrinology Source Type: research
Once-Weekly Basal Insulin Fc Demonstrated Similar Glycemic Control to Once-Daily Insulin Degludec in Insulin-Naive Patients With Type 2 Diabetes: A Phase 2 Randomized Control Trial
CONCLUSIONSOnce-weekly BIF achieved excellent glycemic control similar to degludec, with no concerning hypoglycemia or other safety findings. (Source: Diabetes Care)
Source: Diabetes Care - March 21, 2023 Category: Endocrinology Source Type: research
Cardiovascular Safety in Type 2 Diabetes With Sulfonylureas as Second-line Drugs: A Nationwide Population-Based Comparative Safety Study
CONCLUSIONSOur findings contribute to the understanding that second-line SU for glucose lowering are unlikely to increase CV risk or all-cause mortality. Given their potent efficacy, microvascular benefits, cost effectiveness, and widespread use, this study supports that SU should remain a part of the global diabetes treatment portfolio. (Source: Diabetes Care)
Source: Diabetes Care - March 21, 2023 Category: Endocrinology Source Type: research
Earlier Age at Type 2 Diabetes Diagnosis Is Associated With Increased Genetic Risk of Cardiovascular Disease
CONCLUSIONSIndividuals with an earlier T2D diagnosis have a higher genetic risk of CAD, and this information could be used to tailor lifestyle interventions. (Source: Diabetes Care)
Source: Diabetes Care - March 20, 2023 Category: Endocrinology Source Type: research
Development and Validation of a Diabetic Retinopathy Risk Stratification Algorithm
CONCLUSIONSRelatively simple logistic regression models using nine readily available clinical variables can be used to rank order patients for onset of diabetic eye disease and thereby more efficiently prioritize and target screening for at risk patients. (Source: Diabetes Care)
Source: Diabetes Care - March 17, 2023 Category: Endocrinology Source Type: research
CRP, C-Peptide, and Risk of First-Time Cardiovascular Events and Mortality in Early Type 2 Diabetes: A Danish Cohort Study
CONCLUSIONSThe finding of high hs-CRP as a stronger prognostic biomarker of all-cause mortality than of CVEs may facilitate improved early detection and prevention of deadly diseases besides CVEs. Conversely, elevated C-peptide as a strong CVE biomarker supports the need to target hyperinsulinemia/insulin resistance in T2D CVE prevention. (Source: Diabetes Care)
Source: Diabetes Care - March 17, 2023 Category: Endocrinology Source Type: research
Psychiatric Morbidity in Women With Previous Gestational Diabetes Mellitus: A Nationwide Register-Based Cohort Study
CONCLUSIONSGDM was associated with increased psychiatric morbidity risk. Subsequent diabetes development played a significant role in future psychiatric morbidity risk after GDM, although it only partly explained the association. (Source: Diabetes Care)
Source: Diabetes Care - March 16, 2023 Category: Endocrinology Source Type: research
